ResMed (RMD) Stock Forecast & Price Target

Q: What analysts cover ResMed?

ResMed has been rated by research analysts at Citigroup , Jefferies Financial Group , KeyCorp , Mizuho , Morgan Stanley , Piper Sandler , Robert W. Baird , Rothschild & Co Redburn , Royal Bank Of Canada , The Goldman Sachs Group , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$229.56 +6.57 (+2.95%)

Closing price 03:59 PM Eastern

Extended Trading

$229.64 +0.08 (+0.04%)

As of 05:35 PM Eastern

Compare

ResMed - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 16 Analyst Ratings

Sell
0

Hold
9

Buy
7

Based on 16 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 9 have given a hold rating, and 7 have given a buy rating for RMD.

Consensus Price Target

$241.69
5.28% Upside

According to the 16 analysts' twelve-month price targets for ResMed, the average price target is $241.69. The highest price target for RMD is $300.00, while the lowest price target for RMD is $213.00. The average price target represents a forecasted upside of 5.28% from the current price of $229.56.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RMD Analyst Ratings Over Time

Type	Current Forecast 9/15/25 to 9/15/26	1 Month Ago 8/16/25 to 8/16/26	3 Months Ago 6/17/25 to 6/17/26	1 Year Ago 9/15/24 to 9/15/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	9 Buy rating(s)	11 Buy rating(s)
Hold	9 Hold rating(s)	9 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$241.69	$240.17	$279.82	$278.36
Forecasted Upside	5.28% Upside	6.97% Upside	50.05% Upside	2.57% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed Stock vs. The Competition

Type	ResMed	Healthcare Companies	Broader Market
Consensus Rating Score	2.44	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	5.25% Upside	902.58% Upside	17.02% Upside
News Sentiment Rating	Positive News See Recent RMD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/10/2026	Citigroup 4 of 5 stars	Laura Sutcliffe Not Rated	Reiterated Rating	Neutral
8/31/2026	KeyCorp 2 of 5 stars	Brett Fishbin 1 of 5 stars	Boost Target	Overweight	$255.00 ➝ $267.00	+11.03%
8/19/2026	Rothschild & Co Redburn 4 of 5 stars	Jackson Philips Not Rated	Initiated Coverage	Neutral	$230.00	+4.42%
8/11/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C-) ➝ Hold (C)
8/7/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$213.00	-1.07%
8/7/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Craig Wong-Pan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Perform	$234.00 ➝ $244.00	+15.18%
8/7/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$233.00 ➝ $225.00	+7.36%
8/7/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nathan Treybeck Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$225.00 ➝ $215.00	+1.80%
7/21/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$300.00	+53.10%
7/15/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$235.00 ➝ $220.00	+12.30%
Get the Latest News and Ratings for RMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.
7/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$240.00 ➝ $225.00	+9.78%
7/1/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
6/17/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Bailey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$286.00 ➝ $230.00	+18.48%
4/15/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Low Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight
4/13/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Outperform	$255.00	+11.52%
1/30/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$260.00 ➝ $265.00	+2.78%
9/2/2025	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Outperform
8/1/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
1/31/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
9/26/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$240.00 ➝ $270.00	+11.12%
9/18/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Peer Perform ➝ Underperform	$180.00	-28.25%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:51 PM ET.

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 14, 2026. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

ResMed Inc. recently reported strong financial performance for the quarter ended August 6, 2026, beating analyst expectations with earnings per share of $2.95 against a consensus estimate of $2.89, while revenue of $1.46 billion also met forecasts, demonstrating the company's ability to maintain profitability and meet market expectations in a competitive healthcare environment.
The company has demonstrated consistent revenue growth, with the most recent quarter showing an 8.6% increase compared to the same period last year, and previous quarters in 2026 showing growth rates of 10.8% and 11.0%, indicating a robust demand for its sleep and respiratory care products and software solutions.
ResMed Inc. recently increased its quarterly dividend to $0.66 per share, up from the previous $0.60, representing a 10% increase that provides a higher income stream for investors, with the new dividend scheduled to be paid on September 24, 2026, and offering a yield of approximately 1.2% based on the current stock price.
With a current stock price of $223.05 as of September 14, 2026, ResMed Inc. is trading below its 52-week high of $284.87, potentially offering a more attractive entry point for investors compared to earlier in the year, while still maintaining a market capitalization of $32.175 billion that reflects its significant position in the healthcare equipment sector.
The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.06 and a current ratio of 3.10, indicating ample liquidity and financial stability that can support ongoing operations, research and development, and shareholder returns without excessive reliance on debt financing.

ResMed
Bear Case

Investors should be bearish about investing in ResMed Inc. for these reasons:

ResMed Inc. currently carries a consensus rating of "Hold" from analysts, with a consensus price target of $240.31 as of September 1, 2026, which suggests limited upside potential from the current stock price of $223.05, and recent analyst actions include Wells Fargo lowering its price target to $215.00 and Morgan Stanley reducing its target to $230.00, reflecting cautious sentiment among key institutional investors.
Insider selling activity has been notable, with CEO Michael Farrell selling 4,991 shares on September 8, 2026, and Director Peter Farrell selling 970 shares on September 2, 2026, both under pre-arranged Rule 10b5-1 trading plans, which may signal that company executives are taking advantage of current valuations to reduce their personal holdings, potentially indicating a lack of confidence in near-term stock appreciation.
The stock has experienced significant volatility and recent declines, including a gap down of $16.06 on August 7, 2026, and hitting 52-week lows in May and April 2026, with the current price of $223.05 still well below the 52-week high of $284.87, suggesting that the stock has been under pressure and may continue to face downward momentum if broader market conditions or sector-specific challenges persist.
Short interest in ResMed Inc. has been relatively high, with 13,073,165 shares shorted as of August 31, 2026, representing 9.12% of the float, and days to cover of 8.94, indicating that a significant portion of the stock is being sold by investors who expect the price to decline, which could create additional selling pressure and limit upside potential in the near term.
While ResMed Inc. operates in a growing healthcare sector, it faces intense competition from other medical device companies and potential regulatory challenges, and the company's reliance on specific product lines such as CPAP devices and software platforms may expose it to risks from technological obsolescence, changes in healthcare reimbursement policies, or shifts in consumer preferences toward alternative treatments for sleep-disordered breathing.

RMD Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $241.69, with a high forecast of $300.00 and a low forecast of $213.00.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 9 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.

According to analysts, ResMed's stock has a predicted upside of 5.28% based on their 12-month stock forecasts.

Over the previous 90 days, ResMed's stock had 3 downgrades and 2 upgrades by analysts.

ResMed has been rated by research analysts at Citigroup, Jefferies Financial Group, KeyCorp, Mizuho, Morgan Stanley, Piper Sandler, Robert W. Baird, Rothschild & Co Redburn, Royal Bank Of Canada, The Goldman Sachs Group, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like ResMed more than other "healthcare" companies. The consensus rating score for ResMed is 2.44 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how RMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With ResMed Recommendations

MarketBeat monitors more than a dozen sources for ResMed analyst ratings, with the most recent rating issued on 9/15/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Stock Forecast & Price Target